• F W Albert, H Eichler, H Haubelt, R Loreth, A Matzdorff, D Peetz, G Pindur, H Schinzel, U Seyfert, P Hellstern, and für das Kompetenznetz Hämostaseologie Rheinland-Pfalz-Saarland.
• Klinikum der Stadt Ludwigshafen, Institut für Hämostaseologie und Transfusionsmedizin, Bremserstrasse 79, 67063 Ludwigshafen.
• Hamostaseologie. 2009 Jan 1;29(1):58-63.

AbstractHaemorrhagic disorders must be excluded prior to any operation or other invasive procedure that has the potential to involve serious bleeding. When assessing the individual risk of bleeding, screening tests of hemostasis must be combined with the patient's clinical history and symptoms, and any history of bleeding must be explored under direct medical supervision using a standardized questionnaire. However, this bleeding history is neither very specific, nor is it particularly sensitive. Screening tests that have been found to be useful include platelet count, activated partial thrombo plastin time (aPTT), prothrombin time (PT) and clottable fibrinogen. No reliable, sensitive and specific screening test is however available today to screen for platelet dysfunction or von Willebrand disease. A specialized coagulation laboratory should be involved when the bleeding history or laboratory screening indicate a potential haemorrhagic disorder.

19 keywords...

hide…